Nanoscope Therapeutics

Hear what a Stargardt Macular Degeneration patient in our Clinical Trial has to say about her experience.

Topline Phase 2b Results for MCO-010 in Advanced RP

Phase 2 6-month Results for MCO-010 in Stargardt

Nanoscope Therapeutics is advancing gene therapy using ambient light-sensitive molecules, bringing hope for renewed sight to millions of people blinded by retinal degenerative diseases for which no cure exists.

Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD.

Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.

LEARN ABOUT OUR TECHNOLOGY

Our lead gene therapy product in clinical trials for retinitis pigmentosa will be the first therapy to correct the condition and is applicable for patients with complete or partial degeneration of the retina.

Pioneering a New Wave of Optogenetic Therapeutics for Vision Restoration

LEARN MORE ABOUT OUR PIPELINE

Nanoscope News & Events

Nanoscope Therapeutics Announces Presentations at the World Orphan Drug Congress

Read More

May 22, 2023

Nanoscope Press Release,Home Page
Nanoscope Therapeutics Announces Presentation of Key Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa at the ARVO Annual Meeting

Read More

April 27, 2023

Nanoscope Press Release,Home Page
Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting

Read More

April 13, 2023

Nanoscope Press Release,Home Page
Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa

Read More

March 30, 2023

Nanoscope Press Release,Home Page
Nanoscope Therapeutics Appoints Industry Veteran Vicente Anido Jr., Ph.D., as a Strategic Advisor

Read More

March 20, 2023

Nanoscope Press Release,Home Page
Nanoscope Therapeutics Announces World Health Organization Selection of "Sonpiretigene Isteparvovec" as International Nonproprietary Name for MCO-010

Read More

February 28, 2023

Nanoscope Press Release,Home Page
Nanoscope Therapeutics CEO Sulagna Bhattacharya Joins BIO Health Section Governing Board

Read More

February 13, 2023

Nanoscope Press Release,Home Page
Nanoscope Therapeutics to Present at the BIO CEO & Investor Conference

Read More

February 2, 2023

Nanoscope Press Release,Home Page

READ ALL NANOSCOPE NEWS & EVENTS

Samarendra Mohanty (Co-Founder/President) is an inventor & serial entrepreneur with 20+ years experience in Biomedical Sciences. He is Co-Founder of several Biotechs and Biomedical device /diagnostic companies (developed & commercialized $100K+ biomedical instruments.)

Samar obtained M.Tech in Applied Optics from the Indian Institute of Technology-Delhi and a PhD in (Bio)Physics from the Indian Institute of Sciences-Bangalore.

His extensive Biomedical Technologies experience includes serving as Professor/Senior Scientist at the University of Texas; University of California, Irvine; Center for Adv. Tech (India); Int. Mol. Biotech (Germany); Univ. Pavia (Italy); NUS (Singapore); and University of St. Andrews (UK). He has authored over 200 international patents and publications in leading journals including Nature and Nature Photonics.

He is the Principal Investigator for major grants from the National Eye Institute including Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs an international conference on optogenetics. He is the winner of a 2019 Healthcare Heroes award (Fort Worth Business Press), Retinal Organoid Challenge Award, Audacious Goal Initiative Award (NIH), Finalist of Tech Titan, and NIH-Director’s Innovator Award.